Fig. 3.
Fig. 3. Gel analysis of the proteolytic products generated from the BHK recombinant vWF. (A) Normal plasma vWF (lane 1) and the proteolytic products of WT vWF treated with guanidine HCl (lane 2) and R834W (lane 3) and R834Q mutants (lane 4) analyzed in SDS 1.6% low gelling temperature agarose gel. The horizontal bars marked one of triplet multimers. (B) Proteolytic fragments of WT vWF/guanidine HCl (lane 1) and R834W (lane 2) and R834Q mutants, analyzed by 6% SDS-PAGE under reducing conditions. The blot was probed with anti-vWF and 125I-labeled goat antirabbit IgG. The numbers indicate the MW (×10−3). (C) Proteolytic fragments of WT vWF/guanidine HCl (lanes 1 and 2), R834W mutant (lanes 3 and 4), and R834Q mutant (lanes 5 and 6), analyzed by 6% SDS-PAGE under nonreducing conditions. The vWF products were either analyzed directly (lanes 1, 3, and 5) or subjected to immunoisolation with monoclonal VP-1 before electrophoresis (lanes 2, 4, and 6). The blots were probed as in (B).

Gel analysis of the proteolytic products generated from the BHK recombinant vWF. (A) Normal plasma vWF (lane 1) and the proteolytic products of WT vWF treated with guanidine HCl (lane 2) and R834W (lane 3) and R834Q mutants (lane 4) analyzed in SDS 1.6% low gelling temperature agarose gel. The horizontal bars marked one of triplet multimers. (B) Proteolytic fragments of WT vWF/guanidine HCl (lane 1) and R834W (lane 2) and R834Q mutants, analyzed by 6% SDS-PAGE under reducing conditions. The blot was probed with anti-vWF and 125I-labeled goat antirabbit IgG. The numbers indicate the MW (×10−3). (C) Proteolytic fragments of WT vWF/guanidine HCl (lanes 1 and 2), R834W mutant (lanes 3 and 4), and R834Q mutant (lanes 5 and 6), analyzed by 6% SDS-PAGE under nonreducing conditions. The vWF products were either analyzed directly (lanes 1, 3, and 5) or subjected to immunoisolation with monoclonal VP-1 before electrophoresis (lanes 2, 4, and 6). The blots were probed as in (B).

Close Modal

or Create an Account

Close Modal
Close Modal